Chronic Myelogenous Leukemia

Minot, George R.; Buckman, Thomas E.; Isaacs, Raphael

doi:10.1001/jama.1924.02650450001001

Cited by 168 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In no instance did the haemoglobin level fall more than 1 to 1'5 g/100 ml when hydroxyurea was stopped, which is compatible with a satisfactory clinical state. The cumulative duration of survival of patients submitted to the hydroxyurea-leucopheresis protocol was no different from the survival times of patients treated conventionally with busulphan (Haut et al, 1961;Medical Research Council, 1968) and mitobronitol (Co-operative Study Group, 1972), which were only slightly longer than those obtained by irradiation of the spleen (Medical Research Council, 1968) and therapy with "P (Reinhard et al, 1959), the latter survival time being no different from ithat of untreated patients (Minot et al, 1924).…”

Section: Leucopheresis In Hydroxyurea-treated Patientsmentioning

confidence: 89%

Hydroxyurea, Leucopheresis, and Splenectomy in Chronic Myeloid Leukaemia at the Problastic Phase

Schwarzenberg¹,

Mathé²,

Pouillart³

et al. 1973

BMJ

View full text Add to dashboard Cite

Section: Leucopheresis In Hydroxyurea-treated Patientsmentioning

confidence: 89%

Hydroxyurea, Leucopheresis, and Splenectomy in Chronic Myeloid Leukaemia at the Problastic Phase

Schwarzenberg¹,

Mathé²,

Pouillart³

et al. 1973

BMJ

View full text Add to dashboard Cite

“…20 In 1998, a population-based survey in Norway also described a median survival of 36 months, with an estimated 5-year survival rate of 33%.…”

Section: Survivalmentioning

confidence: 99%

Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis

Dalziel¹,

Round²,

Stein

et al. 2004

Health Technol Assess

103

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

show abstract

“…The only series of untreated patients for which survival data are available is that of Minot, Buckman, and Isaacs (1924). The survival of 52 untreated patients was compared with that of 78 patients treated by irradiation, chiefly from radium.…”

Section: Comparison With Other Seriesmentioning

confidence: 99%

Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia.

1968

BMJ

View full text Add to dashboard Cite

Chronic Myelogenous Leukemia

Cited by 168 publications

References 0 publications

Hydroxyurea, Leucopheresis, and Splenectomy in Chronic Myeloid Leukaemia at the Problastic Phase

Hydroxyurea, Leucopheresis, and Splenectomy in Chronic Myeloid Leukaemia at the Problastic Phase

Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis

Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia.

Contact Info

Product

Resources

About